Discovery and development of heat shock protein 90 inhibitors.

Tony Taldone,Weilin Sun,Gabriela Chiosis

DOI: https://doi.org/10.1016/j.bmc.2008.10.087

IF: 3.461

2009-01-01

Bioorganic & Medicinal Chemistry

Abstract:The different classes of Hsp90 inhibitors are reviewed including natural products such as geldanamycin and radicicol and synthetic inhibitors comprised of purines, pyrazoles, isoxazoles and other scaffolds.

What problem does this paper attempt to address?

Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment

Yong Li,Dongmei Zhang,Jun Xu,Junmin Shi,Lei Jiang,Nan Yao,Wencai Ye

DOI: https://doi.org/10.1016/j.apsb.2012.03.009

IF: 14.903

2012-06-01

Acta Pharmaceutica Sinica B

Abstract:Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that plays a vital role in the signal transduction of cancers. Hsp90 inhibitors are able to inhibit Hsp90 or the complex of Hsp90 and co-chaperones resulting in the degradation of Hsp90-dependent client proteins through the ubiquitination-proteasome pathway, thereby leading to the growth inhibition of tumor cells. This review will briefly discuss the molecular structure and biological function of Hsp90, and focus on a summary of recent progress in the development and testing of natural Hsp90 inhibitors and their different means by which they interact with Hsp90.

pharmacology & pharmacy
[Progress in the study of heat shock protein 90 inhibitors]

Hao-ming Luo,Wei Sun,Jian-yuan Yin,Xiao-hong Yang

Abstract:Heat shock protein 90 is a new target of antitumor drug, the inhibitor of Hsp90 fight against tumor by destroy and degrade the structure of protein. In recent years, looking for Hsp90 inhibitor is not only via structure modifying of natural products, but also via high throughput screening and computer aided drug design to find and synthesize new kinds of Hsp90 inhibitor. Anyway, Hsp90 inhibitor has considered as an important biology target and to pay more and more attention. This review describes recent developments of small molecule Hsp90 inhibitors.
Small Molecule Inhibitors Targeting Heat Shock Protein 90: an Updated Review

Yulong Li,Jinyun Dong,Jiang-Jiang Qin

DOI: https://doi.org/10.1016/j.ejmech.2024.116562

IF: 7.088

2024-01-01

European Journal of Medicinal Chemistry

Abstract:As a molecular chaperone, heat shock protein 90 (HSP90) plays important roles in the folding, stabilization, activation, and degradation of over 500 client proteins, and is extensively involved in cell signaling, proliferation, and survival. Thus, it has emerged as an important target in a variety of diseases, including cancer, neurodegenerative diseases, and viral infections. Therefore, targeted inhibition of HSP90 provides a valuable and promising therapeutic strategy for the treatment of HSP90-related diseases. This review aims to systematically summarize the progress of research on HSP90 inhibitors in the last five years, focusing on their structural features, design strategies, and biological activities. It will refer to the natural products and their derivatives (including novobiocin derivatives, deguelin derivatives, quinone derivatives, and terpenoid derivatives), and to synthetic small molecules (including resorcinol derivatives, pyrazoles derivatives, triazole derivatives, pyrimidine derivatives, benzamide derivatives, benzothiazole derivatives, and benzofuran derivatives). In addition, the major HSP90 small-molecule inhibitors that have moved into clinical trials to date are also presented here.
Heat Shock Protein 90 Inhibitors: an Update on Achievements, Challenges, and Future Directions.

Li,Lei Wang,Qi-Dong You,Xiao-Li Xu

DOI: https://doi.org/10.1021/acs.jmedchem.9b00940

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely associated with refractory diseases, including cancer, neurodegenerative diseases, and viral infections. Clinical Hsp90 inhibitors bind to the ATP pocket in the N-terminal domain of Hsp90 and subsequently suppress the ATPase activity of Hsp90. Recently, with the increased understanding of the discrepancies in the isoforms of Hsp90 and the modes of Hsp90-co-chaperone-client complex interactions, some new strategies for Hsp90 inhibition have emerged. Novel Hsp90 inhibitors that offer selective suppression of Hsp90 isoforms or specific disruption of Hsp90-co-chaperone protein-protein interactions are expected to show with satisfactory efficacy and safety profiles. This review summarizes the recent progress in Hsp90 inhibitors. Additionally, Hsp90 inhibitory strategies are emphasized in this review.
Heat Shock Protein 90 in Neurodegenerative Diseases

Wenjie Luo,Weilin Sun,Tony Taldone,Anna Rodina,Gabriela Chiosis

DOI: https://doi.org/10.1186/1750-1326-5-24

2010-01-01

Molecular Neurodegeneration

Abstract:Hsp90 is a molecular chaperone with important roles in regulating pathogenic transformation. In addition to its well-characterized functions in malignancy, recent evidence from several laboratories suggests a role for Hsp90 in maintaining the functional stability of neuronal proteins of aberrant capacity, whether mutated or over-activated, allowing and sustaining the accumulation of toxic aggregates. In addition, Hsp90 regulates the activity of the transcription factor heat shock factor-1 (HSF-1), the master regulator of the heat shock response, mechanism that cells use for protection when exposed to conditions of stress. These biological functions therefore propose Hsp90 inhibition as a dual therapeutic modality in neurodegenerative diseases. First, by suppressing aberrant neuronal activity, Hsp90 inhibitors may ameliorate protein aggregation and its associated toxicity. Second, by activation of HSF-1 and the subsequent induction of heat shock proteins, such as Hsp70, Hsp90 inhibitors may redirect neuronal aggregate formation, and protect against protein toxicity. This mini-review will summarize our current knowledge on Hsp90 in neurodegeneration and will focus on the potential beneficial application of Hsp90 inhibitors in neurodegenerative diseases.
Pan- and Isoform-Specific Inhibition of Hsp90: Design Strategy and Recent Advances.

Jing Yu,Chao Zhang,Chun Song

DOI: https://doi.org/10.1016/j.ejmech.2022.114516

IF: 7.088

2022-01-01

European Journal of Medicinal Chemistry

Abstract:In the past few decades, the development of heat shock protein 90 (Hsp90) inhibitors for cancer treatment has not stopped. About twenty compounds have been evaluated in the clinical trials, but the FDA approved none of them because of toxic effects and/or not enough efficacies. Insufficient isoform selectivity has been considered as one of the reasons for these failures recently. Therefore, developing isoform-selective Hsp90 inhibitors could probably make great progress in searching for therapeutic agents for cancer as well as many other diseases. Here, we summarized classic pan-inhibitors of Hsp90 based on the classification of binding sites and illustrated design strategies applied in the drug discovery. We summed up current isoform-specific Hsp90 inhibitors including their discovery processes and potential indications.
Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Xin Xie,Nan Zhang,Xiang Li,He Huang,Cheng Peng,Wei Huang,Leonard J Foster,Gu He,Bo Han,Leonard J. Foster

DOI: https://doi.org/10.1016/j.bioorg.2023.106721

IF: 5.307

2023-10-01

Bioorganic Chemistry

Abstract:Heat shock protein 90, also known as Hsp90, is an extensively preserved molecular chaperone that performs a critical function in organizing various biological pathways and cellular operations. As a potential drug target, Hsp90 is closely linked to cancer. Hsp90 inhibitors are a class of drugs that have been extensively studied in preclinical models and have shown promise in a variety of diseases, especially cancer. However, Hsp90 inhibitors have encountered several challenges in clinical development, such as low efficacy, toxicity, or drug resistance, few Hsp90 small molecule inhibitors have been approved worldwide. Nonetheless, combining Hsp90 inhibitors with other tumor inhibitors, such as HDAC inhibitors, tubulin inhibitors, and Topo II inhibitors, has been shown to have synergistic antitumor effects. Consequently, the development of Hsp90 dual-target inhibitors is an effective strategy in cancer treatment, as it enhances potency while reducing drug resistance. This article provides an overview of Hsp90's domain structure and biological functions, as well as a discussion of the design, discovery, and structure-activity relationships of Hsp90 dual inhibitors, aiming to provide insights into clinical drug research from a medicinal chemistry perspective and discover novel Hsp90 dual inhibitors.

biochemistry & molecular biology,chemistry, organic
Recent developments of HSP90 inhibitors: an updated patent review (2020-present)

Jianfeng Liu,Huangliang Shu,Qinxin Xia,Qidong You,Lei Wang

DOI: https://doi.org/10.1080/13543776.2024.2327295

2024-03-09

Expert Opinion on Therapeutic Patents

Abstract:Introduction The 90-kDa heat shock protein (HSP90) functions as a molecular chaperone, it assumes a significant role in diseases such as cancer, inflammation, neurodegeneration, and infection. Therefore, the research and development of HSP90 inhibitors have garnered considerable attention.

pharmacology & pharmacy,chemistry, medicinal
Heat Shock Protein 90 And Role Of Its Chemical Inhibitors In Treatment Of Hematologic Malignancies

Ngoc Ho,Adam Li,Shaoguang Li,Haojian Zhang

DOI: https://doi.org/10.3390/ph5080779

IF: 4.6

2012-01-01

Pharmaceuticals

Abstract:Heat shock protein 90 (Hsp90) is a conserved and constitutively expressed molecular chaperone and it has been shown to stabilize oncoproteins and facilitate cancer development. Hsp90 has been considered as a therapeutic target for cancers and three classes of Hsp90 inhibitors have been developed: (1) benzoquinone ansamycin and its derivatives, (2) radicicol and its derivates, and (3) small synthetic inhibitors. The roles of these inhibitors in cancer treatment have been studied in laboratories and clinical trials, and some encouraging results have been obtained. Interestingly, targeting of Hsp90 has been shown to be effective in inhibition of cancer stem cells responsible for leukemia initiation and progression, providing a strategy for finding a cure. Because cancer stem cells are well defined in some human leukemias, we will focus on hematologic malignancies in this review.
Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Len Neckers,Paul Workman

DOI: https://doi.org/10.1158/1078-0432.ccr-11-1000

IF: 13.801

2012-01-01

Clinical Cancer Research

Abstract:Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, and it is essential for oncogenic transformation. Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clinical trials. Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity. Preclinical data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clinical activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer. Many optimized synthetic, small-molecule Hsp90 inhibitors from diverse chemotypes are now in clinical trials. Here, we review the discovery and development of Hsp90 inhibitors and assess their potential. There has been significant learning from studies of the basic biology of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chemical probes. Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (especially multiple myeloma) in which buffering of proteotoxic stress is critical for survival. We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.

oncology
Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

Chang Gao,Ya-Nan Peng,Hai-Zhou Wang,Shi-Lin Fang,Meng Zhang,Qiu Zhao,Jing Liu

DOI: https://doi.org/10.2174/1381612825666190503145944

IF: 3.31

2019-01-01

Current Pharmaceutical Design

Abstract:Heat shock protein 90 (Hsp90) plays an essential role in various physiological and pathological processes. It activates client proteins to participate in tumor progression. Blocking Hsp90 could enable effective antitumor effects in many tumor types, such as multiple myeloma and colon cancer. Recently, it has motivated an interest in Hsp90 inhibitors that bind to the N-terminal or C-terminal ATP pocket as antitumor drugs. We reviewed the data from experimental and clinical trials on Hsp90 inhibitors in the treatment of different malignancies to explore and summarize their antitumor mechanisms.
Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases

Monimoy Banerjee,Ishita Hatial,Bradley M Keegan,Brian S J Blagg,Bradley M. Keegan,Brian S.J. Blagg

DOI: https://doi.org/10.1016/j.pharmthera.2020.107747

2021-05-01

Abstract:<p>Heat shock protein 90 (Hsp90) is a molecular chaperone that facilitates the maturation of its client proteins including protein kinases, transcription factors, and steroid hormone receptors which are structurally and functionally diverse. These client proteins are involved in various cellular signaling pathways, and Hsp90 is implicated in various human diseases including cancer, inflammation, and diseases associated with protein misfolding; thus making Hsp90 a promising target for drug discovery. Some of its client proteins are well-known cancer targets. Instead of targeting these client proteins individually, however, targeting Hsp90 is more practical for cancer drug development. Efforts have been invested in recognizing potential drugs for clinical use that inhibit Hsp90 activity and result in the prevention of Hsp90 client maturation and dampening of subsequent signaling cascades. Here, we discuss current assays and technologies used to find and characterize Hsp90 inhibitors that include biophysical, biochemical, cell-based assays and computational modeling. This review highlights recent discoveries that N-terminal isoform-selective compounds and inhibitors that target the Hsp90 C-terminus that may offer the potential to overcome some of the detriments observed with pan Hsp90 inhibitors. The tools and assays summarized in this review should be used to develop Hsp90-targeting drugs with high specificity, potency, and drug-like properties that may prove immensely useful in the clinic.</p>

pharmacology & pharmacy
Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Shiro Soga,Shiro Akinaga,Yukimasa Shiotsu

DOI: https://doi.org/10.2174/138161213804143617

IF: 3.31

2013-01-01

Current Pharmaceutical Design

Abstract:Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone which stabilizes various oncogenic kinases, including HER2, EGFR, BCR-ABL, B-Raf and EML4-ALK, which are essential for tumor growth. Several monoclonal antibodies and small molecule kinase inhibitors which target these kinases have been identified as potential new molecular target therapeutics. Previous reports have shown that many oncogenic proteins essential for cancer transformation are chaperoned by the Hsp90 complex, and some of these client proteins have been discovered by using Hsp90 inhibitors, such as geldanamycin (GA) and radicicol (RD).Thus far more than 200 client proteins have been identified. In past derivatives of these natural products have been evaluated in clinical trials, but none of the 1st generation of Hsp90 inhibitors has been approved yet because of their limitations in physico-chemical properties and/or safety profiles. However, recent reports have indicated that more than 10 new agents, 2nd generation of Hsp90 inhibitors with different chemotypes from GA and RD, have entered clinical trials and some of them showed clinical efficacy. In this review article, we describe the discoveries of major Hsp90 client proteins in the cancer field by RD derivatives, the history of KW-2478 discovery and development by Kyowa Hakko Kirin, and gave an update on the current status of new Hsp90 inhibitors in clinical trials.

pharmacology & pharmacy
Progress of study on Hsp90 inhibitors

WANG Qilin,LIU Xiangguo

DOI: https://doi.org/10.13488/j.smhx.2011.04.024

2011-01-01

Abstract:Molecular chaperone heat-shock protein 90(Hsp90) has essential physiological functions in vivo,and is overexpressed in many kinds of tumor cells.As a single agent or in combination with other chemotherapeutic agents,Hsp90 inhibitors have shown anti-tumor effects in preclinical and clinical evaluations.So the molecular chaperone Hsp90 is a potent target in cancer therapy.This review summarized the structure and functions of Hsp90,and the mechanism and current clinical perspectives of Hsp90 inhibitors in order to provide some insights for designing and discovering novel Hsp90 inhibitors in cancer therapy.
HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Alison Maloney,Paul Workman

DOI: https://doi.org/10.1517/14712598.2.1.3

2002-01-01

Expert Opinion on Biological Therapy

Abstract:Current anticancer drug development strategies involve identifying novel molecular targets which are crucial for tumourigenesis. The molecular chaperone heat shock protein (HSP) 90 is of interest as an anticancer drug target because of its importance in maintaining the conformation, stability and function of key oncogenic client proteins involved in signal transduction pathways leading to proliferation, cell cycle progression and apoptosis, as well as other features of the malignant phenotype such as invasion, angiogenesis and metastasis. The natural product HSP90 inhibitors geldanamycin and radicicol exert their antitumour effect by inhibiting the intrinsic ATPase activity of HSP90, resulting in degradation of HSP90 client proteins via the ubiquitin proteosome pathway. Anticancer selectivity may derive from the simultaneous combinatorial effects of HSP90 inhibitors on multiple cancer targets and pathways. 17-allylamino, 17-demethoxygeldanamycin (17AAG), a geldanamycin derivative, showed good activity and cancer selectivity in preclinical models and has now progressed to Phase I clinical trial in cancer patients with encouraging initial results. Phase II trials including combination studies with cytotoxic agents are now being planned and these should allow the therapeutic activity of 17AAG to be determined. Second generation HSP90 inhibitors may be designed to overcome some of the drawbacks of 17AAG, including limited oral bioavailability and solubility. They could also be engineered to target specific functions of HSP90, which may not only provide greater molecular selectivity and clinical benefit but may also increase understanding of the complex functions of this molecular chaperone. HSP90 inhibitors provide proof of concept for drugs directed at HSP90 and protein folding and this principle may be applicable to other medical conditions involving protein aggregation and stability.

medicine, research & experimental,biotechnology & applied microbiology
Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

Taner Erdogan,Fatma Oguz Erdogan

DOI: https://doi.org/10.1080/07391102.2023.2226748

Abstract:Heat shock protein 90 (HSP90) is one of the most attractive targets for research on cancer treatment, and nowadays, many studies carried out for the development of effective HSP90 inhibitors. In the current study, recently published ten natural compounds have been investigated using computer aided drug design (CADD) approach. The study consists of three parts; (1) density functional theory (DFT) calculations including geometry optimizations, vibrational analyses, and molecular electrostatic potential (MEP) map calculations, (2) molecular docking and molecular dynamics (MD) simulations, and (3) binding energy calculations. In DFT calculations, Becke three-parameter hybrid functional with Lee-Yang-Parr correlation functional (B3LYP) and 6-31 + G(d,p) basis set were used. After performing molecular docking calculations, top-scoring ligand-receptor complexes were subjected to MD simulations for 100 ns to investigate the stability of the ligand-receptor complexes and the interactions in more detail. Finally, in binding energy calculations molecular mechanics with Poisson-Boltzmann surface area (MM-PBSA) method was used. The results showed that five of the investigated ten natural compounds have higher binding affinity to HSP90α than that of reference drug Geldanamycin, and could be promising compounds for future studies.Communicated by Ramaswamy H. Sarma.
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications

Mina Ardestani,Zahra Khorsandi,Fariba Keshavarzipour,Siavash Iravani,Hojjat Sadeghi-Aliabadi,Rajender S. Varma

DOI: https://doi.org/10.3390/pharmaceutics14102220

IF: 6.525

2022-10-19

Pharmaceutics

Abstract:Heat shock proteins (Hsps) have garnered special attention in cancer therapy as molecular chaperones with regulatory/mediatory effects on folding, maintenance/stability, maturation, and conformation of proteins as well as their effects on prevention of protein aggregation. Hsp90 ensures the stability of various client proteins needed for the growth of cells or the survival of tumor cells; therefore, they are overexpressed in tumor cells and play key roles in carcinogenesis. Accordingly, Hsp90 inhibitors are recognized as attractive therapeutic agents for investigations pertaining to tumor suppression. Natural Hsp90 inhibitors comprising geldanamycin (GM), reclaimed analogs of GM including 17-AAG and DMAG, and radicicol, a natural macrocyclic antifungal, are among the first potent Hsp90 inhibitors. Herein, recently synthesized heterocyclic compounds recognized as potent Hsp90 inhibitors are reviewed along with the anticancer effects of heterocyclic compounds, comprising purine, pyrazole, triazine, quinolines, coumarin, and isoxazoles molecules.

pharmacology & pharmacy
Discovery of Potent Heat Shock Protein 90 (hsp90) Inhibitors: Structure-Based Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Yonghua Xu,Yunting Zou,Shasha Zhou,Miao-Miao Niu,Yan Zhang,Jindong Li,Zhen Xu,Li Yang

DOI: https://doi.org/10.1080/14756366.2023.2220558

2023-01-01

Journal of Enzyme Inhibition and Medicinal Chemistry

Abstract:Heat shock protein 90 (Hsp90) is considered an attractive therapeutic target for cancer treatment due to its high expression in many cancers. In this study, four potent Hsp90 inhibitors (HPs 1-4) were identified using structure-based virtual screening. Among them, HP-4 exhibited the most potent inhibitory effects (IC50 = 17.64 & PLUSMN; 1.45 nM) against the Hsp90 protein, which was about 7.7 times stronger than that of MPC-3100 (a positive inhibitor targeting Hsp90). In vitro cytotoxicity assay suggested that HP-4 could effectively inhibit the proliferation of a series of tumour cells, including HCT-116, HeLa, A549, A2780, DU145, HepG2 and A498. Furthermore, in vivo assay displayed that HP-4 had significant anti-tumour effects on HCT-116 cell-derived xenograft models. These data demonstrate that HP-4 could be a potential lead compound for the further investigation of anti-tumour drugs.
Inhibitors of the HSP90 Molecular Chaperone: Current Status

Swee Sharp,Paul Workman

DOI: https://doi.org/10.1016/s0065-230x(06)95009-x

2006-01-01

Advances in Cancer Research

Abstract:The molecular chaperone heat shock protein 90 (HSP90) has emerged as an exciting molecular target for cancer therapy. It operates as part of a multichaperone complex and is essential for the conformation, stability, and function of several key oncogenic client proteins such as mutant p53, ERBB2, B-RAF, C-RAF, and CDK4. The HSP90-based chaperone machine is driven by the hydrolysis of ATP and ADP/ATP nucleotide exchange. Many of the inhibitors of HSP90 interrupt the intrinsic ATPase activity, causing degradation of the client proteins via the ubiquitin-proteasome pathway. The first-in-class HSP90 inhibitor in clinical trials is the geldanamycin analog, 17-allylamino, 17-demethoxygeldanamycin (17-AAG). The results that have emerged from these trials have been encouraging, with stable disease observed in two melanoma patients. Pharmacodynamic endpoints, such as induction of HSP70 and downregulation of C-RAF and CDK4 in peripheral blood mononuclear cells and tumor biopsies from treated patients, provided evidence of HSP90 inhibition at well-tolerated doses. The toxicity of 17-AAG has been mild. Several preclinical studies have shown that 17-AAG may enhance the efficacy of a variety of chemotherapeutic agents. Phase II clinical trials in various cancers have been initiated as well as Phase I trials of combined therapy with 17-AAG. However, there are several limitations with 17-AAG such as solubility, stability, and hepatotoxicity. Thus, it is not surprising that new HSP90 agents are under development against this novel target for cancer therapy and several show promise.

oncology

Discovery and development of heat shock protein 90 inhibitors.

Discovery and development of natural heat shock protein 90 inhibitors in cancer treatment

[Progress in the study of heat shock protein 90 inhibitors]

Small Molecule Inhibitors Targeting Heat Shock Protein 90: an Updated Review

Heat Shock Protein 90 Inhibitors: an Update on Achievements, Challenges, and Future Directions.

Heat Shock Protein 90 in Neurodegenerative Diseases

Pan- and Isoform-Specific Inhibition of Hsp90: Design Strategy and Recent Advances.

Small-molecule dual inhibitors targeting heat shock protein 90 for cancer targeted therapy

Recent developments of HSP90 inhibitors: an updated patent review (2020-present)

Heat Shock Protein 90 And Role Of Its Chemical Inhibitors In Treatment Of Hematologic Malignancies

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

Inhibition of Heat Shock Protein 90 As a Novel Platform for the Treatment of Cancer.

Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases

Hsp90 Inhibitors as Anti-Cancer Agents, from Basic Discoveries to Clinical Development

Progress of study on Hsp90 inhibitors

HSP90 as a new therapeutic target for cancer therapy: the story unfolds

Probing some recent natural compounds from Phellinus baumii, Colletotrichum sp. and Ligustrum lucidum as heat shock protein 90 inhibitors

Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications

Discovery of Potent Heat Shock Protein 90 (hsp90) Inhibitors: Structure-Based Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

Inhibitors of the HSP90 Molecular Chaperone: Current Status